Eli Lilly And Co vs Wendys Co — how do they compare? Eli Lilly And Co trades at $1,224.7 (market cap $1.08T), while Wendys Co trades at $8.55 (market cap $1.44B). The key difference: Eli Lilly And Co is far larger — about 750× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| LLY | WEN | |
|---|---|---|
Market Cap | $1.08T | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $10.68 |
52-Week Low | $639.43 | $6.17 |
Enterprise Value | $1.13T | $5.17B |
Dividend Yield | 0.57% | 3.71% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
WEN trades at $8.595, up 17.74% in 24 hours, with a neutral technical signal. Recent Q2 2026 EPS of $0.18 beat expectations, but revenue trends are flat and net income margin declined to 5.72% in 2025. The company cut its dividend and withdrew 2026 guidance amid a strategic turnaround under new leadership, facing traffic declines and loss of its No. 2 U.S. burger chain position to Burger King.
Outlook is cautious; the dividend cut frees cash for restructuring, but execution risks are high. Valuation appears reasonable with a P/E of 11.44, though high debt and competitive pressures pose significant headwinds. Analyst consensus is mixed, with 62.75% hold ratings reflecting uncertainty around the turnaround plan's success.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →